Japanese company profile · 7446

TOHOKU CHEMICAL CO., LTD.

English company name recorded in Japan's EDINET filer data.

Original Japanese company name: 東北化学薬品株式会社

Name follows the English name recorded in EDINET filer data. English company name source

FY2024 · fiscal year ended September 2025Latest filing date: 2025-12-17

What does this company do?

What does this company do?

In its FY2024 public filing, TOHOKU CHEMICAL CO., LTD. reports Industry, Medical Services, Academy of Life Sciences. The page shows business-level revenue and profit where the source disclosures support comparison.

TOHOKU CHEMICAL CO., LTD.'s largest reported business by revenue in FY2024 was Industry.

FY2024 · fiscal year ended September 2025 · View original filing ↗ The source document may be in Japanese.

Reported company-wide figures

Company revenue
¥34.44B ↗
FY2024 · fiscal year ended September 2025
Operating profit
¥518.39M ↗
FY2024 · fiscal year ended September 2025
Comparable margin
1.5% ↗
FY2024 · fiscal year ended September 2025

JGAAP · Consolidated company-wide

Company profile

Company profile

Identity

Securities code
7446
EDINET code
E02810
Corporate number
5420001009282
Listing status
Listed
Industry (EDINET filer classification)
Wholesale trade

Location and fiscal year

Headquarters
青森県弘前市 · As filed in Japanese
Fiscal year end
9month
Latest fiscal year
FY2024
Accounting standard
JGAAP
P16 data snapshot
2026-11-07

Company size

Employees (consolidated)
315 people (FY2024)
Employees (non-consolidated)
245 people (FY2024)
Capital stock
JPY 820.4 million (FY2024)

Official information

Public information is organized and presented by P16. EDINET filer list (2026-11-07) Opens in a new tab · EDINET PDL 1.0 terms Opens in a new tab

Business structure

How does it make money?

FY2024 · fiscal year ended September 2025 · Business Sales Segment profit (loss)
BusinessSalesShare of company sales
Industry¥17.86B ↗51.9%51.9%Sales to external customers: ¥17.86B ↗
Medical Services¥14.14B ↗41.1%41.1%Sales to external customers: ¥14.14B ↗
Academy of Life Sciences¥2.44B ↗7.1%7.1%Sales to external customers: ¥2.44B ↗

All values are in Japanese yen (JPY). No currency conversion is applied. FY2024 · fiscal year ended September 2025. Revenue and profit are shown only where the filing and data support a comparison. “—” means a comparable amount was not disclosed. We compare sales to outside customers for each business and the company as a whole, using the same filing, fiscal year and scope. Reported business sales may include sales between businesses. We leave the share blank when the figures cannot be matched.

Company revenue

Company-wide trend

Company revenue

JGAAP · Consolidated
  1. FY202097.0¥36.22B
  2. FY2021100.0¥37.33B
  3. FY202294.0¥35.09B
  4. FY202386.1¥32.16B
  5. FY202492.3¥34.44B

Company operating profit

JGAAP · Consolidated
  1. FY202075.5¥713.15M
  2. FY2021100.0¥944.03M
  3. FY202279.6¥751M
  4. FY202337.4¥353.26M
  5. FY202454.9¥518.39M

Only reported years are shown. Missing years are left blank; accounting standards and scopes are kept in separate series.

What has changed?

Businesses reported in earlier filings

Reporting labels alone do not prove that a business started, ended, merged, or changed its identity.

  • 化学工業薬品 (Original Japanese label)FY 2020–FY 2022 · Source
  • 臨床検査試薬 (Original Japanese label)FY 2020–FY 2022 · Source
  • Food ProductsFY 2020–FY 2022 · Source

What is growing?

What is growing?

Business revenue growth

This describes a reported period; it is not a forecast.

What has changed?

What has changed?

A five-year business-mix comparison is not shown because the available filings do not provide five comparable years on the same basis.

Source

Company profile

These scores summarize company characteristics using public filings. Comparison groups vary by measure. Higher is not always better.

  • Growth7
    Peer-position scoreFY2024
  • Profitability18
    Peer-position scoreFY2024
  • Business concentration21
    Peer-position scoreFY2024
  • Business change44
    Peer-position scoreFY2023→FY2024
  • Cash generation17
    Peer-position scoreFY2024
  • Growth persistence19
    Peer-position scoreFY2020→FY2021, FY2021→FY2022, FY2022→FY2023, FY2023→FY2024

Next

Ask about this company

Source

Public filing

FY2024 · fiscal year ended September 2025

The source document may be in Japanese.

Filing ID: S100XAMG

View original filing ↗
Original Japanese label
Original Japanese label
化学工業薬品
Original Japanese label
臨床検査試薬

根拠となる資料